For more than 25 years, MUSC has been South Carolina’s leader in bone marrow and stem cell transplantation. We are the only combined adult and pediatric FACT (Foundation for Accreditation of Cellular Therapy) accredited and NCI-Designated Cancer Center in the state.
MUSC's experience and innovation with adult and pediatric blood and marrow transplantation have resulted in outcomes that are among the best in the country. Our internationally recognized team of specialists and researchers have reduced associated complications making transplantation possible for people not previously eligible. As a pioneer in blood and marrow transplant research, MUSC is the definitive source offering hope for many adult and pediatric patients battling Hodgkin's disease, non-Hodgkin's lymphoma, leukemia, multiple myeloma and other diseases. We are one of a few U.S. programs to have used bone marrow to treat autoimmune diseases, sickle cell disease and other red blood cell-related diseases.
According to a national, mutivariate report including the years 2014, 2015, and 2016, MUSC achieved an overall survival rate of 76.1% for patients receiving first allogeneic transplants, above the national average of 70.6%.
Press Ganey announced November 12 the recipients of five prestigious awards - with the Blood & Marrow Transplant Program at the Medical University of South Carolina (MUSC) receiving the Team of the Year award from a pool of 60 applicants.
The blood and marrow transplant team is the strength of our program and encompasses all of the specialists involved in treating and caring for patients. The team includes dedicated hematologists/oncologists, nurses, blood bank and cryopreservation and an HLA laboratory. These individuals collaborate to ensure each patient receives the care and information necessary for a successful outcome. Each week, the team reviews individual cases, makes treatment recommendations and appointments that accommodate patients’ schedules and preferences. During these meetings, the team also identifies patients who might benefit from joining a clinical trial. The transplant coordinator is the main point of contact between the patient and the team and he or she will be completely familiar with each patient’s needs.
At MUSC, patients do not have to wait for a blood or marrow transplant. We specialize in quick access and immediate treatment. Our Blood and Marrow Transplant team creates an individualized treatment plan that is unique to each patient's needs and provides curative therapy for a broad range of illnesses. We also provide opportunities for patients to participate in clinical trials, including several for the prevention and treatment of graft versus host disease.
Along with state-of-the-art treatments, Hollings assists patients in dealing with the financial, physical and emotional aspects of having cancer.
Personalized patient care is at the center of everything we do. And no one tells the story better than our patients themselves. Meet some of our patients and hear about their cancer journey.Patient Stories
As an NCI-designated cancer center, Hollings is part of a national network of clinical trials, with access to hundreds of trials across the United States.